Swiss Life Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$171M Buy
680,811
+3,342
+0.5% +$719K 0.71% 23
2026
Q1
$147M Buy
677,469
+48,777
+8% +$10.8M 0.72% 23
2025
Q4
$144M Sell
628,692
-243,460
-28% -$55.5M 0.73% 18
2025
Q3
$202M Sell
872,152
-2,032
-0.2% -$414K 1.05% 14
2025
Q2
$162M Sell
874,184
-18,356
-2% -$3.41M 0.96% 18
2025
Q1
$187M Buy
892,540
+70,708
+9% +$13.7M 1.36% 14
2024
Q4
$146M Buy
821,832
+404,776
+97% +$74.4M 1.08% 16
2024
Q3
$82.3M Sell
417,056
-11,711
-3% -$2.19M 0.94% 17
2024
Q2
$73.5M Buy
428,767
+44,550
+12% +$7.38M 0.87% 19
2024
Q1
$70M Buy
384,217
+37,699
+11% +$6.5M 0.97% 18
2023
Q4
$53.7M Buy
346,518
+12,253
+4% +$1.79M 0.65% 23
2023
Q3
$49.8M Buy
334,265
+41,456
+14% +$6.09M 0.77% 20
2023
Q2
$39.5M Buy
292,809
+4,991
+2% +$732K 0.58% 26
2023
Q1
$45.9M Buy
287,818
+53,478
+23% +$8.18M 0.69% 20
2022
Q4
$37.9M Sell
234,340
-17,235
-7% -$2.64M 0.63% 26
2022
Q3
$33.8M Buy
251,575
+14,020
+6% +$2.01M 0.58% 29
2022
Q2
$36.4M Sell
237,555
-78,849
-25% -$12M 0.59% 29
2022
Q1
$51.3M Buy
316,404
+4,099
+1% +$595K 0.72% 18
2021
Q4
$42.3M Sell
312,305
-51,861
-14% -$6.13M 0.55% 30
2021
Q3
$39.3M Buy
364,166
+5,951
+2% +$680K 0.54% 33
2021
Q2
$34.3M Buy
358,215
+37,624
+12% +$4.24M 0.35% 44
2021
Q1
$34.7M Sell
320,591
-7,638
-2% -$817K 0.5% 35
2020
Q4
$35.2M Buy
328,229
+247,577
+307% +$23.8M 0.51% 35
2020
Q3
$7.06M Sell
80,652
-53,249
-40% -$5.01M 0.1% 153
2020
Q2
$13.2M Buy
133,901
+26,119
+24% +$2.3M 0.21% 99
2020
Q1
$8.21M Buy
107,782
+52,111
+94% +$4.44M 0.16% 124
2019
Q4
$4.93M Sell
55,671
-46,819
-46% -$3.89M 0.09% 186
2019
Q3
$7.76M Sell
102,490
-529,360
-84% -$36.3M 0.1% 148
2019
Q2
$45.9M Buy
631,850
+55,245
+10% +$4.34M 0.55% 46
2019
Q1
$46.5M Sell
576,605
-13,485
-2% -$1.1M 0.59% 46
2018
Q4
$54.4M Sell
590,090
-148,039
-20% -$13M 1.11% 20
2018
Q3
$69.8M Sell
738,129
-417,203
-36% -$39.6M 0.94% 19
2018
Q2
$107M Buy
1,155,332
+324,209
+39% +$31.7M 1.6% 7
2018
Q1
$78.7M Buy
831,123
+475,920
+134% +$52.3M 1.38% 12
2017
Q4
$34.4M Sell
355,203
-78,707
-18% -$7.42M 0.77% 36
2017
Q3
$38.5M Buy
433,910
+54,293
+14% +$4.13M 1.03% 22
2017
Q2
$27.5M Buy
379,617
+23,609
+7% +$1.59M 0.71% 32
2017
Q1
$23.2M Buy
356,008
+80,422
+29% +$5.06M 0.63% 40
2016
Q4
$17.3M Buy
275,586
+61,337
+29% +$3.74M 0.58% 56
2016
Q3
$13.5M Buy
214,249
+58,125
+37% +$3.76M 0.46% 57
2016
Q2
$9.66M Hold
156,124
0.4% 72
2016
Q1
$8.92M Sell
156,124
-25,926
-14% -$1.45M 0.38% 72
2015
Q4
$10.8M Buy
182,050
+10,926
+6% +$629K 0.48% 61
2015
Q3
$9.31M Buy
171,124
+38,910
+29% +$2.53M 0.45% 64
2015
Q2
$8.88M Sell
132,214
-4,921
-4% -$321K 0.31% 66
2015
Q1
$8.03M Buy
+137,135
New +$8.28M 0.32% 71

Other funds holding ABBV

Swiss Life Asset Management's ABBV Position: Q2 2026 in Review

Swiss Life Asset Management increased its AbbVie (ABBV) stake by 0.49% in Q2 2026, buying an estimated $719K and bringing the position to 680,811 shares worth $171M. The position accounts for 0.71% of the portfolio, ranked #23.

Swiss Life Asset Management first reported a position in ABBV in Q1 2015 and has held it in 46 quarters since. The position peaked at $202M in Q3 2025. 3,317 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Swiss Life Asset Management held 680,811 shares of AbbVie worth $171M as of Q2 2026.
  • Swiss Life Asset Management bought 3,342 AbbVie shares in Q2 2026, an estimated $719K.
  • AbbVie made up 0.71% of Swiss Life Asset Management's portfolio in Q2 2026, its #23 holding.
  • Swiss Life Asset Management first reported a position in AbbVie in Q1 2015 and has held it in 46 quarters since.
  • Swiss Life Asset Management's AbbVie position peaked at $202M in Q3 2025.
  • 3,317 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.